CLBCore Laboratories Inc.
Is the price fair?
The yardsticks disagree: cheap against its own 5-year P/E range (14th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.
Priced for ~11% a year FCF growth. The price already bakes in strong, sustained growth.
Cheap vs its own history: P/E 19.4 vs a 25.6 median over 14 quarters (−24% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CLB's price assumes
Core Laboratories Inc. trades at 19.4× earnings against 24.6× for the median Oil & Gas Equipment & Services name, cheaper than its own group.
Trailing P/E · Oil & Gas Equipment & Services median 24.6 · cheaper than the typical name in its group
- Price / sales
- 1.47
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.2%
Free cash flow yield · Oil & Gas Equipment & Services median 5.9%
- Growth the price implies
- +11%
Growth the price implies · The price pays for +11% free cash flow growth a year for a decade; the business has delivered −0.84% a year over the last three.
Details›
- Price / bookas of 2026-Q1
- 2.88
- EV / EBITas of 2026-Q1
- 20.4
- EV / salesas of 2026-Q1
- 1.75
- Energy median P/E157 names
- 16.0
- Oil & Gas Equipment & Services median P/E34 names
- 24.6
- Free cash flow, trailing twelve months
- $15M
- Market capitalisation
- $469M
- 3-year revenue growth
- +0.61%
- 3-year free cash flow growth
- −0.84%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $11.74 |
| Its own P/E history, median | $13.30 |
| Its own P/E history, upper quartile | $14.30 |
| 52-week range | $9.71 – $19.64 |
| Today | $10.08 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.